Overall, TRP helps to improve DME recurrence after vitreous drug injection, additional laser may help to suppress VEGF production in the ischemic area, and combination therapy of TRP and anti-VEGF drugs may help reduce the frequency of vitreous drug injections, patient treatment costs, number of clinic visits, and adverse events (eg, endophthalmitis, retinal detachment). The gene discussed is VEGFA; the disease is retinal detachment.